Galectin Therapeutics Inc. (GALT)
GALT Stock Price Chart
Explore Galectin Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze GALT price movements and trends.
GALT Company Profile
Discover essential business fundamentals and corporate details for Galectin Therapeutics Inc. (GALT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Sept 2002
Employees
15.00
Website
https://galectintherapeutics.comCEO
Joel Lewis
Description
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
GALT Financial Timeline
Browse a chronological timeline of Galectin Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.09.
Earnings released on 15 May 2026
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%.
Earnings released on 31 Mar 2026
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%.
Earnings released on 14 Nov 2025
EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%.
Earnings released on 14 Aug 2025
EPS came in at -$0.12 surpassing the estimated -$0.16 by +25.00%.
Earnings released on 15 May 2025
EPS came in at -$0.15 surpassing the estimated -$0.20 by +25.00%.
Earnings released on 31 Mar 2025
EPS came in at -$0.19 falling short of the estimated -$0.16 by -18.75%, while revenue for the quarter reached $36.00k .
Earnings released on 14 Nov 2024
EPS came in at -$0.18 surpassing the estimated -$0.20 by +10.00%.
Earnings released on 13 Aug 2024
EPS came in at -$0.20 falling short of the estimated -$0.16 by -25.00%.
Earnings released on 15 May 2024
EPS came in at -$0.19 falling short of the estimated -$0.16 by -18.75%.
Earnings released on 29 Mar 2024
EPS came in at -$0.16 matching the estimated -$0.16, while revenue for the quarter reached $80.00k .
Earnings released on 13 Nov 2023
EPS came in at -$0.24 falling short of the estimated -$0.16 by -50.00%.
Earnings released on 14 Aug 2023
EPS came in at -$0.15 surpassing the estimated -$0.21 by +28.57%.
Earnings released on 15 May 2023
EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%.
Earnings released on 30 Mar 2023
EPS came in at -$0.18 falling short of the estimated -$0.17 by -5.88%.
Earnings released on 14 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.20 by +30.00%.
Earnings released on 15 Aug 2022
EPS came in at -$0.16 surpassing the estimated -$0.19 by +15.79%.
Earnings released on 16 May 2022
EPS came in at -$0.17 falling short of the estimated -$0.10 by -70.00%.
Earnings released on 31 Mar 2022
EPS came in at -$0.13 surpassing the estimated -$0.19 by +31.58%.
Earnings released on 15 Nov 2021
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%.
Earnings released on 16 Aug 2021
EPS came in at -$0.15 surpassing the estimated -$0.18 by +16.67%.
GALT Stock Performance
Access detailed GALT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
